Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
AstraZeneca
Colorcon
McKesson
McKinsey

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for CUDC-907

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug CUDC-907: Patents, clinical trial progress, indications

CUDC-907 is an investigational drug.

There have been 13 clinical trials for CUDC-907. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Lymphoma, Head and Neck Neoplasms, and Thyroid Carcinoma, Anaplastic. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and Aarhus University Hospital.

There are ten US patents protecting this investigational drug and one hundred and three international patents.

Recent Clinical Trials for CUDC-907
TitleSponsorPhase
Fimepinostat in Treating Brain Tumors in Children and Young AdultsCannonball Kids' Cancer FoundationEarly Phase 1
Fimepinostat in Treating Brain Tumors in Children and Young AdultsCuris, Inc.Early Phase 1
Fimepinostat in Treating Brain Tumors in Children and Young AdultsPacific Pediatric Neuro-Oncology ConsortiumEarly Phase 1

See all CUDC-907 clinical trials

Clinical Trial Summary for CUDC-907

Top disease conditions for CUDC-907
Top clinical trial sponsors for CUDC-907

See all CUDC-907 clinical trials

US Patents for CUDC-907

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CUDC-907   See Pricing Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Curis, Inc. (Lexington, MA)   See Pricing
CUDC-907   See Pricing Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Curis, Inc. (Lexington, MA)   See Pricing
CUDC-907   See Pricing Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Curis, Inc. (Lexington, MA)   See Pricing
CUDC-907   See Pricing Phosphoinositide 3-kinase inhibitors with a zinc binding moiety Curis, Inc. (Lexington, MA)   See Pricing
CUDC-907   See Pricing Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Curis, Inc. (Lexington, MA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CUDC-907

Drugname Country Document Number Estimated Expiration Related US Patent
CUDC-907 Australia 2012236367 2031-04-01   See Pricing
CUDC-907 Brazil 112013025340 2031-04-01   See Pricing
CUDC-907 Canada 2830822 2031-04-01   See Pricing
CUDC-907 Chile 2013002823 2031-04-01   See Pricing
CUDC-907 China 103582483 2031-04-01   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Harvard Business School
Merck
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.